Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
NASA Partners with Katalyst to Save Swift Observatory with Innovative Docking Mission 
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off 
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay 
Eisai Co. and Biogen Inc. hope to gain approval with the Japanese health ministry by the end of the year of an Alzheimer's drug that could both treat the cause and slow symptom progression.
The U.S. Food and Drug Administration granted it fast-track approval earleir in the month.
Eisai, a Japanese firm, had applied with the European Medicines Agency on Jan 9 for approval to sell the medicine in Europe. It also submitted the drug data to China's National Medical Products Administration in December.
Using an antibody called Lecanemab, the new drug co-developed by Eisai and US-based Biogen is for early-stage treatment of the fatal, brain-robbing disease.
The drug removes a type of protein called amyloid beta, which accumulates inside the brain and destroys nerve cells, Eisai said.
The firm said clinical trials demonstrated the new drug curbed the progression of symptoms, such as worsening memory and impairment in judgment, by 27 percent compared with a placebo.
According to the clinical trial results, 12 to 17 percent of those who were administered the drug showed side effects, such as brain edema and bleeding, compared with a group who took a placebo, but most of those who had the side effects only suffered mild to moderate symptoms temporarily, Eisai said.
It is expected that the drug will be expensive after Eisai set its price in the United States at $26,500 per year.
In December 2021, a panel at Japan's health ministry refused to approve another Alzheimer's disease drug jointly developed by Eisai and Biogen.
